Literature DB >> 14604984

Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy.

Anders Olofsson1, Johannes H Ippel, Sybren S Wijmenga, Erik Lundgren, Anders Ohman.   

Abstract

The human plasma protein transthyretin (TTR) may form fibrillar protein deposits that are associated with both inherited and idiopathic amyloidosis. The present study utilizes solution nuclear magnetic resonance spectroscopy, in combination with hydrogen/deuterium exchange, to determine residue-specific solvent protection factors within the fibrillar structure of the clinically relevant variant, TTRY114C. This novel approach suggests a fibril core comprised of the six beta-strands, A-B-E-F-G-H, which retains a native-like conformation. Strands C and D are dislocated from their native edge region and become solvent-exposed, leaving a new interface involving strands A and B open for intermolecular interactions. Our results further support a native-like intermolecular association between strands F-F' and H-H' with a prolongation of these beta-strands and, interestingly, with a possible shift in beta-strand register of the subunit assembly. This finding may explain previous observations of a monomeric intermediate preceding fibril formation. A structural model based on our results is presented.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604984     DOI: 10.1074/jbc.M310605200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Characterizing intermolecular interactions that initiate native-like protein aggregation.

Authors:  Francesco Bemporad; Alfonso De Simone; Fabrizio Chiti; Christopher M Dobson
Journal:  Biophys J       Date:  2012-06-05       Impact factor: 4.033

2.  Probing the conformation of a prion protein fibril with hydrogen exchange.

Authors:  Steven M Damo; Aaron H Phillips; Anisa L Young; Sheng Li; Virgil L Woods; David E Wemmer
Journal:  J Biol Chem       Date:  2010-08-02       Impact factor: 5.157

3.  Heating of proteins as a means of improving crystallization: a successful case study on a highly amyloidogenic triple mutant of human transthyretin.

Authors:  Anders Karlsson; A Elisabeth Sauer-Eriksson
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-07-21

4.  A structural model of an amyloid protofilament of transthyretin.

Authors:  Bruno E Correia; Nuno Loureiro-Ferreira; J Rui Rodrigues; Rui M M Brito
Journal:  Protein Sci       Date:  2005-12-01       Impact factor: 6.725

Review 5.  Amyloid formation by globular proteins under native conditions.

Authors:  Fabrizio Chiti; Christopher M Dobson
Journal:  Nat Chem Biol       Date:  2009-01       Impact factor: 15.040

Review 6.  Structural insights into functional and pathological amyloid.

Authors:  Frank Shewmaker; Ryan P McGlinchey; Reed B Wickner
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

7.  Amyloid-like fibrils from a domain-swapping protein feature a parallel, in-register conformation without native-like interactions.

Authors:  Jun Li; Cody L Hoop; Ravindra Kodali; V N Sivanandam; Patrick C A van der Wel
Journal:  J Biol Chem       Date:  2011-06-28       Impact factor: 5.157

8.  Determination of amyloid core structure using chemical shifts.

Authors:  Lukasz Skora; Markus Zweckstetter
Journal:  Protein Sci       Date:  2012-10-26       Impact factor: 6.725

9.  Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.

Authors:  J Rui Rodrigues; Carlos J V Simões; Cândida G Silva; Rui M M Brito
Journal:  Protein Sci       Date:  2010-02       Impact factor: 6.725

10.  Amide solvent protection analysis demonstrates that amyloid-beta(1-40) and amyloid-beta(1-42) form different fibrillar structures under identical conditions.

Authors:  Anders Olofsson; Malin Lindhagen-Persson; A Elisabeth Sauer-Eriksson; Anders Ohman
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.